In the late 1990s, the National Institutes of Health funded an article on testosterone replacement therapy that promoted its effectiveness.
It’s a bit like the famous “The Power of Myth” story, except this time the myth is that testosterone therapy can save your life.
But, as a former patient of the National Institute of Allergy and Infectious Diseases (NIAID), I want to debunk these myths.
I’ve spent the last two decades researching testosterone replacement and have seen first-hand the devastating side effects of such treatments.
The article that was funded by NIAID claimed that testosterone replacement treatment can save up to 80 percent of all men with prostate cancer.
This was based on the results of a meta-analysis published in the American Journal of Clinical Nutrition in 2005, which found that “the most common adverse effect of testosterone replacement is increased libido and erectile dysfunction.”
The study did not include the effect of men taking testosterone alone.
But it did look at how testosterone replacement treatments affected erectile function.
For example, the study showed that men taking 100 mg of testosterone daily for five days had “increased erectile functioning.”
It also noted that there was a significant correlation between increased libidos and “increase in erectile desire and ejaculation frequency” and decreased erectile sensitivity.
The study concluded that “a combination of treatment with testosterone and counseling of patients with prostate hypertrophy” would improve sexual function in men with hyperprolactinemia.
This conclusion was based largely on studies that found that the combination of testosterone and testosterone-releasing medication “did not appear to decrease sexual desire or sexual function.”
The NIAIDs study was criticized for its methodological flaws.
However, it did provide a solid basis for its conclusion that the treatment of men with cancer can have a significant effect on their sexual function.
The problem with the study was that it used very crude measures of erectile performance and erections, which is not how men with the disease should be treated.
This means that men who are prescribed the hormone and who are not receiving treatment are still experiencing “enhancement” and are also likely to experience side effects.
This is a problem that NIAIDS also found with other studies that looked at the effects of testosterone on men with chronic obstructive pulmonary disease, or COPD.
It is also a problem for men with meningitis, a common viral infection.
For men with COPD, testosterone injections are often the first treatment to be tried, but this is often not a very effective treatment.
The researchers looked at whether a combined testosterone injection with testosterone-blocking medication was more effective than placebo.
The testosterone-blocker medication significantly decreased the erectile response in men who had taken the testosterone injections, but it did not affect the erections of men who did not take the testosterone treatment.
It also did not reduce the erectility of men whose testosterone treatment did not cause side effects or increase erectile responses.
In short, testosterone treatments have been shown to have a dramatic effect on erectile functions, but they do not have a long-term effect on sexual function or sexual dysfunction.
These studies also showed that testosterone-induced hypogonadism, which can cause infertility and lead to prostate cancer, was much more common in men taking the combined testosterone treatment than in men on testosterone alone alone.
In other words, men who take testosterone alone and are not getting treatment are likely to have less success than those who receive testosterone-based therapy.
The NIIHS study also did a poor job of measuring erectile and ejaculatory function.
While the men who were taking the testosterone had higher testosterone levels than the placebo group, the men in the testosterone group had significantly lower levels of both of these indicators.
This indicates that men on the testosterone-only treatment group experienced lower erectile activity, and this could be due to a reduction in testosterone itself.
The men taking an estrogen-based treatment were also less likely to achieve an erection and were more likely to ejaculate.
It was unclear if the testosterone therapy also decreased the sexual response in the men on estrogen treatment.
But the results suggest that the combined treatment had little effect on men’s sexual response.
In contrast, men on a testosterone-and-estrogen therapy treatment had significantly more erectile arousal than men on an estrogen treatment alone.
The results of this study showed an effect of the combined hormone treatment on erections but not on ejaculatory activity.
This suggests that, although testosterone treatment increases libido, it does not have an effect on the libido of the men with high levels of testosterone.
So, the conclusion of this NIA ID study that testosterone treatments can significantly reduce libido in men is likely correct.
But men who use testosterone-free testosterone injections and testosterone therapy alone might be more at risk of adverse sexual effects.
The fact that the NIAids study did find an effect from testosterone treatment on sexual desire and erectility should raise red flags about the validity of these results.
But these findings do not